Tag: Mauna
Mauna Kea: towards a joint venture with Tasly Pharmaceuticals
(CercleFinance.com) – Mauna Kea Technologies announces the signing of a strategic agreement with Tasly Pharmaceuticals to create a joint venture (JV). Under the terms of the agreement, this joint venture…
Mauna Kea Technologies announces the publication of a meta-analysis demonstrating the significant role of Cellvizio in the detection of dysplasia and cancer of the esophagus – 07/06/2022 at 18:00
Paris and Boston, July 6, 2022 – 6:00 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces…
Mauna Kea Technologies: new authorization in the United States – 2022-04-12 at 18:15
(AOF) – Mauna Kea Technologies announces the first 510(k) clearance from the FDA for the use of the Cellvizio in a new category of endoscopic, laparoscopic and needle procedures guided…
Mauna Kea: new authorization from the United States FDA
(CercleFinance.com) – Mauna Kea Technologies announces today a new authorization from the American FDA for the use of the Cellvizio 100 Series platform. This US FDA authorization concerns a new…
Mauna Kea will collaborate with On Target Laboratories
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? To sell ? What course objective? Our experts engage…
Mauna Kea Technologies: start of recruitment for a multicenter clinical trial – 02/22/2022 at 18:06
(AOF) – Mauna Kea Technologies announces that, as part of its collaboration with Johnson & Johnson’s Lung Cancer Initiative (LCI), initial patient recruitment has begun in a prospective, multicenter, open-label,…
Mauna Kea Technologies: 2022 financial calendar
Through Alexandra Saintpierre Published on 01/24/2022 at 8:22 p.m. Photo credit © Mauna Kea …
Mauna Kea Technologies on the rise after its savings plan – 01/14/2022 at 11:58
(AOF) – Mauna Kea Technologies gained 4.35% to 0.74 euro, supported by the presentation of its cost savings plan. This plan will allow the medtech to focus its financial resources…
Rebirth in sight for Mauna Kea
Subscribe for 1 € Unlimited access to all advice Over 800 securities listed in Paris and abroad scrutinized. To buy ? To sell ? What course objective? Our experts get…
Mauna Kea Technologies: Armistice Capital Master Fund Ltd has sold shares
Through Alexandra Saintpierre Posted on 12/23/2021 at 9:20 p.m. (Boursier.com) – By letter received on December 22 at the AMF, the American company Armistice Capital, LLC, acting on behalf of…
Mauna Kea Technologies, biggest drop in SRD at the close of Wednesday, December 22, 2021
(AOF) – Mauna Kea Technologies (-3.85% at 0.63 euro) Medtech was penalized by its low value, which generates high volatility. © AOF Legal disclaimer The AOF information reproduced on Capital.fr…
Mauna kea tech: Armistice Capital drops below 5% of capital
Receive free each morning the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and,…